PA5-52488

antibody from Invitrogen Antibodies

Targeting: ZSCAN1 FLJ33779, ZNF915

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-52488

Provider

Invitrogen Antibodies

Product name

ZSCAN1 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Immunogen sequence: QPSLKHTKGG TQEAVAGISV VPRGPRGGRP FQCADCGMVF TWVTHFIEHQ KTHREEGPFP CPECGKVFLH NSVLTEHGKI HLLEPPRKKA PRSKGPRESV PPRDGAQGPV APRSPKRPFQ CSVCGKAFPW MVHLIDHQKL

Concentration

0.20 mg/mL

References

Submitted references

ZSCAN1 Autoantibodies Are Associated with Pediatric Paraneoplastic ROHHAD.

Mandel-Brehm C, Benson LA, Tran B, Kung AF, Mann SA, Vazquez SE, Retallack H, Sample HA, Zorn KC, Khan LM, Kerr LM, McAlpine PL, Zhang L, McCarthy F, Elias JE, Katwa U, Astley CM, Tomko S, Dalmau J, Seeley WW, Pleasure SJ, Wilson MR, Gorman MP, DeRisi JL
Annals of neurology 2022 Aug;92(2):279-291

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent staining of ZSCAN1 in human cell line U-2 OS shows positivity in nucleoli. Samples were probed using a ZSCAN1 Polyclonal Antibody (Product # PA5-52488).

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical staining of ZSCAN1 in human cerebral cortex tissue shows strong nuclear positivity in neuronal cells. Samples were probed using a ZSCAN1 Polyclonal Antibody (Product # PA5-52488).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

2 FIGURE Validation of autoantibodies to ZSCAN1 in ROHHAD patients. In panel a and b, enrichment of ZSCAN1 by PhIP-Seq and RLBA was compared between ROHHAD patients (n = 9), non-inflammatory healthy controls (n = 24), and pediatric controls including children with OMS with and without NT (n = 25) and an obesity patient with NT (n = 1). Data represent the average of 2 independent technical replicates. a, PhIP-Seq analysis. Each column represents an individual sample. A heatmap of total ZSCAN1 RP100K is shown in the top row. To enable comparisons between the majority of samples with lower signal we added a ceiling value of 1,000 RP100K. Z-Score enrichments based on our 100 human donor dataset are plotted below, with samples that have Z-score enrichments >3 colored with blue squares. Gray squares indicate Z-score

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

4 FIGURE Validation of ZSCAN1 autoantibodies in CSF and sera of ROHHAD patients using 293 T CBAs. (A) CSF: Immunocytochemistry with 293T cells expressing full-length ZSCAN1 and immunostaining with CSF (1:10) from ROHHAD patients and commercial antibody to ZSCAN1 (rabbit, 1:1000 Invitrogen). Anti-human IgG-488 was used to visualize human IgG, and anti-rabbit IgG-567 was used to visualize anti-ZSCAN1 commercial antibody. Exposure times and post-image processing and thresholding was kept constant across conditions within the experiment. Co-localization was assessed qualitatively through observance of yellow in merged images. (B) Sera: Immunocytochemistry with 293T cells expressing full-length ZSCAN1 and immunostaining with sera (1:100) from ROHHAD patients and commercial antibody to ZSCAN1 (rabbit, 1:1000 Invitrogen). Anti-human IgG-488 was used to visualize human IgG, and anti-rabbit IgG-567 was used to visualize anti-ZSCAN1 commercial antibody. Exposure times and post-image processing and thresholding was kept constant across conditions within the experiment. Co-localization was assessed qualitatively through observance of yellow in merged images. Note colocalization in ROHHAD Sera-1 and -3.